[Form 4] Kestra Medical Technologies, Ltd. Insider Trading Activity

Rhea-AI Filing Summary

On 07/17/2025 Kestra Medical Technologies (KMTS) filed a Form 4 for CFO Vaseem Mahboob. The executive acquired 22,059 restricted stock units (RSUs) at no cost (code A). Following the grant, his direct ownership rose to 36,897 common shares.

The RSUs will vest in three equal tranches: 7,353 shares on 17 Jul 2026 and 2027, and 7,354 shares on 17 Jul 2028, subject to continued service. Mahboob also holds 159,000 stock options; 79,500 options vest on 06 Mar 2026, with the remaining 79,500 vesting monthly over the subsequent year. No sale or cash purchase occurred; the transaction represents routine equity compensation aimed at retention and alignment of incentives.

No other insider activity or material company information is disclosed in this filing.

Insights

Financial Analyst

TL;DR: Routine RSU grant increases CFO ownership; negligible immediate market impact.

The Form 4 reflects a standard compensation award rather than an open-market buy. The 22,059 RSUs raise Mahboob’s stake by roughly 149%, signalling commitment but not indicating an independent valuation view. Vesting through 2028 supports long-term retention. The 159,000 options, already disclosed in prior filings, carry the same vesting schedule, so dilution effects were anticipated. With no cash outlay or new financing, the filing is neutral for valuation and liquidity. Investors may see modestly positive governance optics, but trading impact should be minimal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Mahboob Vaseem

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES, LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WA 98033

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/17/2025		A		22,059(1)	A	$0.00	36,897	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(2)							(2)	03/06/2035	Common Shares	159,000		159,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest 7,353 on July 17, 2026, 7,353 on July 17, 2027 and 7,354 on July 17, 2028.

2. Includes 79,500 options that will vest on March 6, 2026, and the remaining 79,500 will vest monthly over the following year.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Vaseem Mahboob	07/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.